Stem Cells and Exosomes — What Is Approved vs. What Is Sold

A patient came in last week with a glossy brochure — umbilical cord stem cells, IV infusion, optional exosome booster, for fatigue and joint pain. FDA-registered lab, IRB-approved protocol, tens of thousands of dollars. I didn't know where to start.

Start by separating four questions the brochure collapses into one: what approved stem cell therapy actually is, what's physically in their syringe, what it plausibly does once it's in, and what the regulatory status of that specific product is.

Okay — what does approved actually look like?

Allogeneic hematopoietic stem cell transplantation — cells from a matched donor that reconstitute a patient's entire blood system after myeloablative conditioning. Curative in acute leukemias, aplastic anemia, sickle cell, severe combined immunodeficiency. Decades of registry data. Transplant-related mortality measured in whole percentage points. That's the benchmark.

And the reason it works is specific to the biology, right?

Exactly. The hematopoietic stem cell has a defined niche. You empty the marrow to make room. Engraftment is documented by chimerism testing — you measure donor DNA in the blood. Nothing is inferred from symptom improvement. That rigor is what makes it medicine.

So when a clinic borrows that credibility for an IV infusion with no conditioning and no matching — nothing about that transfers.

Nothing. And the product in the syringe is probably not what the brochure says. "Umbilical cord stem cells" in a commercial setting is usually one of two things: Wharton's jelly extract that independent labs have repeatedly shown contains few or no viable cells, or culture-expanded mesenchymal stromal cells — stromal, not stem, because the field stopped using that word — grown to a target dose.

Why does the name matter?

Because culture expansion — growing cells outside the body to scale — is what converts the product into a drug under FDA rules. Any clinic administering those cells without an approved Biologics License Application or an IND — an Investigational New Drug application allowing a formal trial — is operating outside the law. FDA-registered lab means the facility is on a list. It does not mean the product is approved.

What about the exosome booster?

Extracellular vesicles — membrane-bound particles cells release, carrying proteins and RNA — are genuinely interesting in early research. But the International Society for Extracellular Vesicles is explicit: most commercial preparations are heterogeneous vesicle mixtures with no demonstrated endosomal origin. On a clinic invoice, exosomes means concentrated conditioned medium. Evidence base: mechanistic and animal data only. No completed trials with clinical endpoints in humans for longevity or fatigue indications.

Are there any serious safety signals?

FDA's MedWatch has cases of severe infections, emboli, and blindness from unregulated cell products. No systematic registry, so true incidence is unknown — but the adverse events that have been reported are not trivial.

So what do I actually tell the patient?

Three things. First, ask the clinic for the product's IND number or BLA number — if they can't provide one, the product is unapproved. Second, IRB approval means a committee reviewed a protocol, not that the treatment works. Third, the money is gone before the first infusion. There is no refund if it doesn't help.

And the single thing you'd want me to remember?

Approved cell therapy is not gentle — it requires conditioning, matching, and specialist monitoring. Any offer that skips all of that and promises systemic renewal is borrowing credibility from a science it doesn't belong to.